The increasing demand for precision in diagnostic processes continues to propel growth in the HLA typing market. Rising incidences of genetic diseases and a greater number of organ transplants are fueling this surge. The application of HLA typing in identifying the severity of genetic diseases and validating compatibility between organ donors and recipients is bolstering market growth. Significant advancements in HLA-typing related products are set to further stimulate this upward trajectory.
Major players in this space are regularly launching innovative products, whilst rising awareness of HLA typing is expected to continue to bolster market growth. Notably, the high prevalence of genetic diseases across nations has essentially necessitated the adoption of HLA testing for disease identification. With the prominence associated with organ and bone marrow transplantation, we anticipate the HLA typing market will persist in its growth. Despite the potential challenges brought by small study populations and rigorous regulatory frameworks, the rising prevalence of diseases and developments in HLA typing provide a solid foundation for continued market expansion.
COVID-19 impacted the HLA typing market to a great extent due to the use of HLA typing in identifying the severity of COVID-19 diseases. For instance, according to a study published in 2021 by the European Journal of Medical Research, the HLA-A*11:01, HLA-B*51:01, and HLA-C*14:02 alleles were significantly associated with severe disease or worse outcomes. This led to increased adoption of HLA typing for COVID-19 patients to understand the severity of the disease, driving the market growth. However, the market growth is stabilizing in the current scenario after COVID-19 as the worldwide restrictions have eased down and disease screening services have been resumed.
The factors such as the growing burden of genetic diseases and the increasing number of organ transplants aid as a major contributors to the market growth. Furthermore, advancements in the products related to HLA typing are also expected to boost market growth.
According to the CDC data updated in May 2022, Sickle Cell Disease (SCD) affects approximately 100,000 Americans in 2021. Furthermore, according to news-medical.net updated in August 2022, thalassemia affects around 4.4 out of every 10,000 live births throughout the world every year. Such a high prevalence of genetic diseases across the globe will lead to increased adoption of HLA testing for the identification of genetic diseases, driving market growth.
Furthermore, rising initiatives from the key market players for the launch of innovative products into the market will further be expected to drive the growth of this market. For instance, in November 2021, NGeneBio a South Korean diagnostics firm received CE-IVD marking for its next-generation sequencing-based human leukocyte antigen (HLA) typing assay. This HLAaccuTest detects 11 HLA gene loci to verify the histocompatibility between bone marrow or organ donors and recipients before transplantation. This will lead to increased adoption of HLA typing tests during organ and bone marrow transplantation propelling the market growth.
In addition, rising awareness of HLA typing is also expected to bolster market growth. For instance, in August 2021, a free HLA typing test camp was conducted at Dr. Vinky Rughwani Thalassemia and Sickle Cell Center in collaboration with Sankalp India Foundation. Such campaigns will therefore lead to increased adoption of HLA typing for genetic testing, driving the market growth.
Thus, the rising prevalence of diseases and the developments in HLA typing are expected to drive market growth. However, small size of study population and ethical concern and stringent regulatory framework are expected to hinder the growth of the market.
HLA Typing Market Trends
Hospital Segment is Expected to Exhibhit a Significant Market Growth in the HLA Typing MarketThe hospital segment is expected to grow at a significant rate in the HLA typing market, due to the increasing number of organ transplants and the developing infrastructure of hospitals in terms of advanced devices and equipment. For instance, Cambridge University Hospital provides HLA typing tests for solid organ transplantation, hematopoietic stem cell transplantation, and also for the diagnosis of various diseases, such as rheumatoid arthritis, narcolepsy, and behçet's disease, among others.
Furthermore, according to organdonor.gov updated in March 2022, the number of organ donors and transplantations took place in 2021 for various organs such as kidneys, livers, and hearts in the United States include, 90,483, 11,891, 3,502, and 24,670, 9,236 and 3,817 respectively. Such a huge number of organ transplants that takes place in hospitals will therefore lead to increased adoption of HLA typing tests in the hospitals, thereby driving this segment growth.
In addition, rising initiatives by the hospitals for the conduction of camps and bone marrow donation programs will further drive the growth of this segment. For instance, in May 2022, on the occasion of World Thalassemia Day, Aster Hospitals held a stem-cell donor drive in collaboration with I Love To Care (India) Charitable Trust and DKMS-BMST Foundation India to increase awareness and provide hope for children with thalassemia. The drive was organized to encourage people to come forward and register as stem cell donors. Such initiatives will lead to increased adoption of HLA testing in hospitals to match the bone marrow of patients, driving this segment's growth.
Therefore, owing to the above-mentioned factors, the hospital segment is expected to register significant growth over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast PeriodNorth America is expected to be a dominant region in the HLA Typing market, owing to the rising burden of genetic diseases and government initiatives to create awareness among people. According to the NIH in May 2022, it is estimated that the funding in the United States for organ transplantation was USD 208 million and USD 201 million in 2020 and 2021 respectively. The high funding for organ translation by the United States will lead to rising in the number of organ translations, thereby rising HLA typing adoption, and driving the market growth in this region.,
Furthermore, according to the Organ Procurement and Transportation Network in January 2022, in the United States, 41,354 organ transplants were carried out in 2021, up 5.9 percent from the previous year and breaking the 40,000 mark for the first time. Such a high number of organ transplantations in developed countries will lead to increased adoption of the HLA typing market, driving the market growth over the forecast period.
In addition, the rising launch of HLA products by the key market players from the United States is also expected to drive market growth in this region. For instance, in March 2022, Immucor launched Mia Fora NGS Express HLA Typing Software. which gives users of Mia Fora NGS MFlex HLA Typing assays a faster and easier NGS analysis experience. Such type of HLA typing software will lead to increased adoption of HLA typing, thereby driving the market growth in this region.
Therefore, these above-mentioned factors are expected to fuel the growth of the HLA typing market in North America.
HLA Typing Market Competitor AnalysisThe market for HLA typing market is slightly fragmented due to the rise in the number of product launches by many biotechnological companies, the rise in innovative biotechnological companies, rise in genetic testing, among others. Some of the key players that are expected to dominate the HLA Typing market include Thermofisher Scientific Inc., Qiagen, Illumina Inc., F. Hoffman-La Roche Limited, Bio-Rad Laboratories Inc., Beckton, Dickinson and Company, TBG Diagnostics Ltd, Takara Bio Inc., GenDX, and Omixon Inc, among others.
Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Growing Burden of Genetic Diseases
4.2.2 Increasing Number of Organ Transplantation
4.2.3 Rising Government Initiatives Related to Advanced Diagnostics
4.3 Market Restraints
4.3.1 Small Size of Study Population and Ethical Concern
4.3.2 Stringent Regulatory Framework
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.2 Reagents and Consumables
5.1.3 Softwares and Services
5.2 By Application
5.3 By End User
5.3.2 Research Laboratories
5.3.3 Other End Users
5.4.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.4.4 Middle East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle East and Africa
5.4.5 South America
22.214.171.124 Rest of South America
6.1.1 Beckton, Dickinson and Company
6.1.2 Bio-Rad Laboratories Inc.
6.1.3 F. Hoffman-La Roche Limited
6.1.5 Illumina Inc.
6.1.6 Omixon Inc.
6.1.8 Takara Bio Inc.
6.1.9 TBG Diagnostics Ltd
6.1.10 Thermofisher Scientific Inc.
A selection of companies mentioned in this report includes:
- Beckton, Dickinson and Company
- Bio-Rad Laboratories Inc.
- F. Hoffman-La Roche Limited
- Illumina Inc.
- Omixon Inc.
- Takara Bio Inc.
- TBG Diagnostics Ltd
- Thermofisher Scientific Inc.